talampanel

Talampanel is a synthetic small molecule and a derivative of dioxolo-benzodiazepine that acts as a potent, selective, noncompetitive antagonist of the alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor, an ionotropic glutamate receptor in the central nervous system. By binding allosterically to AMPA receptors at the so-called "GYKI site," it inhibits excitatory neurotransmission mediated by glutamate. Talampanel was developed primarily as an antiepileptic drug but has also been investigated for other neurological conditions including malignant gliomas, amyotrophic lateral sclerosis (ALS), Parkinson disease, and dyskinesias. Although it showed some efficacy in clinical trials for epilepsy and ALS, its development was discontinued due to poor pharmacokinetic properties—specifically its short half-life requiring multiple daily doses—and lack of significant efficacy in pivotal studies[1][2][4][5][6].

Brand names

Talvesta

Other names

talampanel (INN)(-)-talampanelAmpanelKinampa